Valacyclovir oral suspension - Hyloris Pharmaceuticals
Alternative Names: HF-029; HY-029; HY-REF-029Latest Information Update: 20 Mar 2024
At a glance
- Originator Hyloris Pharmaceuticals
- Class Antivirals; Branched-chain amino acids; Essential amino acids; Hypoxanthines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Infections
Highest Development Phases
- Clinical Phase Unknown Herpesvirus infections
Most Recent Events
- 14 Mar 2024 Hyloris Pharmaceuticals plans another pivotal trial for Herpesvirus infections in the first half of 2024
- 26 Dec 2023 Clinical trials in Herpesvirus infections (PO) before December 2023
- 26 Dec 2023 Hyloris Pharmaceuticals announces intention to submit NDA to US FDA for Herpes viruses infections in 2024